Internal Medicine, Hematology & Oncology · Stuart, FL
NPI
1841633286
Since 2013
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
501 SE Osceola St Ste 301
Stuart, FL, 34994
Phone (772) 223-5945
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.7M
351,743 services
Medicare patients, 2024
852
Average age 77
Drug cost, 2024
$10.1M
2,694 prescriptions
Company payments, 2025
$4,721
From 53 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ravi K Patel was code J1439 (injection, ferric carboxymaltose, 1 mg), 134,250 times for 81 patients. In total Ravi K Patel billed 351,743 services in 163 codes, and Medicare paid $4.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 134,250 | 81 | $0.87 | $116K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,200 | 12 | $28.43 | $517K |
| J0185 Injection, aprepitant, 1 mg | Office | 11,700 | 19 | $1.34 | $16K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 11,400 | 24 | $4.39 | $50K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 11,100 | 60 | $0.10 | $1,151 |
| J0897 Injection, denosumab, 1 mg | Office | 7,860 | 30 | $20.10 | $158K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,735 | 16 | $0.08 | $624 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 6,336 | 18 | $19.23 | $122K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 5,250 | 11 | $0.10 | $544 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,543 | 56 | $0.09 | $312 |
| 85025 Blood Count | Office | 2,656 | 490 | $7.61 | $20K |
| 36415 Venipuncture Blood Collection | Office | 1,791 | 428 | $8.64 | $15K |
| 80053 Clinical Chemistry | Office | 1,685 | 427 | $10.35 | $17K |
| 99214 Office E&M - Established | Office | 1,518 | 473 | $99.85 | $152K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,040 | 12 | $0.08 | $79.81 |
By year: 2022 $2.7M for 162,420 services; 2023 $3.9M for 242,640 services; 2024 $4.7M for 351,743 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,656 | 490 | $7.61 | $20K |
| 36415 Venipuncture Blood Collection | 1,791 | 428 | $8.64 | $15K |
| 80053 Clinical Chemistry | 1,685 | 427 | $10.35 | $17K |
| 82728 Clinical Chemistry | 501 | 238 | $13.36 | $6,693 |
| 82607 Clinical Chemistry | 372 | 214 | $14.78 | $5,498 |
| 82746 Clinical Chemistry | 370 | 214 | $14.41 | $5,332 |
| 84443 Clinical Chemistry | 232 | 100 | $16.46 | $3,819 |
| 83550 Clinical Chemistry | 232 | 159 | $8.57 | $1,988 |
| 83540 Clinical Chemistry | 230 | 158 | $6.34 | $1,458 |
| 84100 Clinical Chemistry | 188 | 85 | $4.65 | $874 |
Medicare prescription drug claims, 2024
In 2024, the drug Ravi K Patel prescribed most often to Medicare patients was Dexamethasone, with 154 prescriptions and refills. In total Ravi K Patel wrote 2,694 Medicare prescriptions that cost $10.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 154 | 175 | 85 | $3,004 |
| Ondansetron Hcl Generic | 123 | 131 | 79 | $1,943 |
| Eliquis Apixaban | 118 | 140 | 28 | $80K |
| Acyclovir Generic | 109 | 160 | 24 | $1,714 |
| Prednisone Generic | 98 | 112 | 27 | $581 |
| Revlimid Lenalidomide | 85 | 87 | 16 | $1.6M |
| Abiraterone Acetate Generic | 80 | 80 | 12 | $116K |
| Hydroxyurea Generic | 80 | 181 | 23 | $2,332 |
| Prochlorperazine Maleate Generic | 79 | 87 | 57 | $1,118 |
| Lenalidomide Generic | 66 | 66 | 11 | $848K |
| Xarelto Rivaroxaban | 62 | 112 | 12 | $61K |
| Olanzapine Odt Olanzapine | 49 | 54 | 30 | $821 |
| Tagrisso Osimertinib Mesylate | 48 | 48 | Under 11 | $761K |
| Gabapentin Generic | 38 | 52 | 11 | $306 |
| Olanzapine Generic | 38 | 58 | 19 | $880 |
Brand drugs: 1,010 claims; generic drugs: 1,684 claims; opioid claims: 144.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ravi K Patel $4,721 ($4,721 in general payments such as food, travel and fees) from 53 companies. The largest payer was Janssen Biotech, Inc. with $677.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 31 | $677 |
| Pfizer Inc. PFE | 22 | $384 |
| Abbvie Inc. ABBV | 14 | $261 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $257 |
| GlaxoSmithKline, LLC. GSK | 10 | $248 |
| Daiichi Sankyo Inc. 4568.T | 12 | $241 |
| Astellas Pharma US Inc 4503.T | 10 | $211 |
| Celgene Corporation BMY | 6 | $174 |
| Exelixis Inc. EXEL | 5 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 10 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.